Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

348
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
348
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

299
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
299
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

367
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
367
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

5.0K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.0K
Other Disorders of Digestive System01:30

Other Disorders of Digestive System

1.3K
The gastrointestinal tract is susceptible to various disorders. If the lower esophageal sphincter is damaged, stomach acid can flow back into the esophagus, causing irritation and inflammation of the lining. This condition is called gastroesophageal reflux disease (known as heartburn) and may cause chest pain and difficulty swallowing. In the stomach, prolonged use of nonsteroidal anti-inflammatory drugs like aspirin, chronic alcohol consumption, bacterial infections such as Helicobacter...
1.3K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.8K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between cumulative glucocorticoid exposure and epicardial adipose tissue volume in systemic lupus erythematosus.

EULAR rheumatology open·2026
Same author

Occupational category, job type, and sarcoidosis: Findings from a French multicenter study.

Pulmonology·2026
Same author

Glomeruloid haemangioma in Erdheim-Chester disease: An atypical skin manifestation associated with elevated vascular endothelial growth factor-A levels.

British journal of haematology·2026
Same author

Efficacy and Tolerance of Cladribine for Non-Langerhans Cell Histiocytosis.

European journal of haematology·2026
Same author

Serum lipidomic and metabolomic signatures link epicardial adipose tissue to cardiovascular diseases in SLE: a post-hoc analysis.

Lupus science & medicine·2026
Same author

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis.

Blood cancer journal·2026
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Related Experiment Video

Updated: Dec 27, 2025

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.9K

Erdheim-Chester disease.

Julien Haroche1, Fleur Cohen-Aubart1, Zahir Amoura1

  • 1Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Service de Médecine Interne 2, Maladies Auto-Imunes et Systémiques, Centre National de Référence des Histiocytoses, Hôpital Pitié-Salpêtrière, Paris, France.

Blood
|February 29, 2020
PubMed
Summary
This summary is machine-generated.

Erdheim-Chester disease (ECD) involves foamy histiocyte infiltration, often driven by MAPK pathway mutations like BRAFV600E. Targeted therapies show promise for severe ECD cases.

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.8K
Interrogating Individual Autoreactive Germinal Centers by Photoactivation in a Mixed Chimeric Model of Autoimmunity
11:12

Interrogating Individual Autoreactive Germinal Centers by Photoactivation in a Mixed Chimeric Model of Autoimmunity

Published on: April 11, 2019

7.4K

Related Experiment Videos

Last Updated: Dec 27, 2025

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.9K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.8K
Interrogating Individual Autoreactive Germinal Centers by Photoactivation in a Mixed Chimeric Model of Autoimmunity
11:12

Interrogating Individual Autoreactive Germinal Centers by Photoactivation in a Mixed Chimeric Model of Autoimmunity

Published on: April 11, 2019

7.4K

Area of Science:

  • Histiocytosis and Inflammatory Myeloid Neoplasms

Background:

  • Erdheim-Chester disease (ECD) is a rare histiocytosis characterized by foamy CD68+CD1a- histiocyte infiltration.
  • MAPK pathway activating mutations, particularly BRAFV600E (57-70%) and MAP2K1 (~20%), are identified in over 80% of ECD patients.
  • ECD is now classified as an inflammatory myeloid neoplasm, with 15% co-occurring with Langerhans cell histiocytosis (LCH) and 10% associated with myeloproliferative/myelodysplastic syndromes.

Purpose of the Study:

  • To summarize the key characteristics, clinical manifestations, and treatment landscape of Erdheim-Chester disease.
  • To highlight the significance of MAPK pathway mutations in ECD pathogenesis and therapeutic targeting.
  • To discuss the prognostic implications of central nervous system involvement and the evolving treatment strategies.

Main Methods:

  • Review of clinical data and literature on Erdheim-Chester disease.
  • Analysis of mutation profiles, focusing on MAPK pathway alterations.
  • Evaluation of treatment outcomes for various therapeutic approaches, including targeted therapies.

Main Results:

  • Common ECD manifestations include long bone involvement (80-95%), hairy kidney (63%), coated aorta (40%), and right atrium infiltration (36%).
  • Central nervous system involvement is a critical predictor of mortality.
  • Interferon-α is a recommended initial treatment, while BRAF and MEK inhibitors offer high efficacy for refractory/multisystem ECD.

Conclusions:

  • Targeted therapies (BRAF/MEK inhibitors) demonstrate robust efficacy in severe ECD with no acquired resistance observed to date.
  • These targeted therapies may be best reserved for severe cases due to potential adverse effects and unknown long-term consequences.
  • Continued research is essential for understanding ECD's complex biology and optimizing patient management.